LOGIN  |  REGISTER
Assertio
C4 Therapeutics

Oscar Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 20, 2023 | Last Trade: US$15.75 0.47 3.08

NEW YORK / Dec 20, 2023 / Business Wire / Oscar Health, Inc. (“Oscar”) (NYSE: OSCR), a leading healthcare technology company, today announced that Chief Executive Officer, Mark Bertolini, is scheduled to present and provide a business update at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at approximately 9:00 AM PT (12:00 PM ET) in San Francisco, CA.

All interested parties are invited to listen to a live webcast of the presentation by visiting www.ir.hioscar.com and selecting the “Events & Presentations” link. Following the presentation, a webcast replay will be available on Oscar’s investor relations website for a period of 30 days.

About Oscar Health

Oscar Health, Inc. (“Oscar”) is the first health insurance company built around a full stack technology platform and a relentless focus on serving its members. At Oscar, our mission is to make a healthier life accessible and affordable for all. Headquartered in New York City, Oscar has been challenging the health care system's status quo since our founding in 2012. The company’s member-first philosophy and innovative approach to care has earned us the trust of nearly one million members, as of September 30, 2023. We offer Individual & Family, Small Group and Medicare Advantage plans, and +Oscar, our full stack technology platform, to others within the provider and payor space. Our vision is to refactor health care to make good care cost less. Refactor is a term used in software engineering that means to improve the design, structure, and implementation of the software, while preserving its functionality. At Oscar, we take this definition a step further. We improve our members’ experience by building trust through deep engagement, personalized guidance, and rapid iteration.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page